PPARG and Parkinson disease: Coupled with large language models (LLMs) trained on biomedical literature and clinical trial databases, researchers could rapidly screen FDA-approved drugs for repurposing candidates (e.g., anti-diabetic agents targeting PPARγ) that mitigate both motor and non-motor symptoms in PD-RBD (92).